Peptide Comparison
Ipamorelin vs Tesamorelin + Ipamorelin
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Tesamorelin + Ipamorelin has stronger documented evidence (FDA-Approved (component)) than Ipamorelin (Anecdotal + Phase 2) while both occupy the ghrp / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Tesamorelin + Ipamorelin is the safer pick. Ipamorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Ipamorelin | Tesamorelin + Ipamorelin | |
|---|---|---|
| Class | Growth hormone-releasing peptide (GHRP); ghrelin receptor agonist | FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | Selective GHS-R1a (ghrelin receptor) agonist on pituitary; no cortisol or prolactin rise | Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover. |
| Route | SC injection | SC injection |
| Half-life | ~2 hrs | Tesamorelin ~26 min (plasma); Ipamorelin ~2 hrs |
| Dosage (research) | 200 mcg SC 2x daily (Seeds Vol 1 starting protocol, range up to 300 mcg 3x daily per r/Peptides wiki, often stacked with CJC-1295 no-DAC) | 1 mg Tesamorelin + 200 mcg Ipamorelin SC nightly (5 nights/wk). Cycle 12-16 weeks on / 4-6 weeks off |
| Evidence tier | Anecdotal + Phase 2 | FDA-Approved (component) |
| Research depth | 64 indexed | — |
| Availability | Compounding Restricted | Compounding Restricted |
| Reported risks | Mild fatigue; headache; injection site reactions; elevated IGF-1 theoretical | Tesamorelin component carries FDA-label pancreatitis and hyperglycaemia warnings; injection-site reactions; theoretical IGF-1 elevation; cost is high (Tesamorelin compounded form is expensive) |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Ipamorelin or Tesamorelin + Ipamorelin?
Tesamorelin + Ipamorelin has stronger documented evidence (FDA-Approved (component)) than Ipamorelin (Anecdotal + Phase 2) while both occupy the ghrp / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Tesamorelin + Ipamorelin is the safer pick. Ipamorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between Ipamorelin and Tesamorelin + Ipamorelin?
Ipamorelin is classed as Growth hormone-releasing peptide (GHRP); ghrelin receptor agonist; Tesamorelin + Ipamorelin is classed as FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend. Reported mechanism: Ipamorelin, Selective GHS-R1a (ghrelin receptor) agonist on pituitary; no cortisol or prolactin rise; Tesamorelin + Ipamorelin, Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover. Reported half-life: Ipamorelin, ~2 hrs; Tesamorelin + Ipamorelin, Tesamorelin ~26 min (plasma); Ipamorelin ~2 hrs. Routes in published studies: Ipamorelin, SC injection; Tesamorelin + Ipamorelin, SC injection.
Which has stronger evidence, Ipamorelin or Tesamorelin + Ipamorelin?
Tesamorelin + Ipamorelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Ipamorelin is graded Anecdotal + Phase 2, with 9 cited sources on its reference page and 64 indexed studies. Tesamorelin + Ipamorelin is graded FDA-Approved (component), with 3 cited sources on its reference page.
Which is more accessible, Ipamorelin or Tesamorelin + Ipamorelin?
Neither Ipamorelin nor Tesamorelin + Ipamorelin is an FDA-approved drug. Catalog status: Ipamorelin, Compounding Restricted; Tesamorelin + Ipamorelin, Compounding Restricted. FDA lists Ipamorelin in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023).
Are Ipamorelin and Tesamorelin + Ipamorelin ever combined?
Ipamorelin and Tesamorelin + Ipamorelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…